Current guidelines recommend mTOR inhibitor therapy as a potential first-line systemic treatment for advanced PEComas, highlighting its prominent role in achieving disease control in this ultra-rare sarcoma.45,48. The gene discussed is MTOR; the disease is neoplasm with perivascular epithelioid cell differentiation.